Update: Exelixis Presents Strong Data at ASCO
Exelixis presented interim data from Phase II clinical trials for its lead cancer drug candidate at the 2011 meeting of the American Society of Clinical Oncology. Reported data were for multiple tumor types. Here is a brief on some of the results.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.